UK-based Babylon Health, which offers AI-based services, will go public through a SPAC merger at a valuation of $4.2B
Just when you thought the SPAC had been played out, London-based healthtech Babylon confirms the rumours and announces its plan to go public via a $4.2 billion merger …
Context & Ripple Effects
Babylon's SPAC announcement caps a five-year private run that reads as a valuation ladder: a $25M Series A in 2016, a $60M raise in 2017 to sharpen its diagnostic AI, a $100M hiring pledge for 500-plus researchers, and a $550M Series C from Saudi Arabia's PIF and Kinnevik in 2019 that priced it above $2B. The $4.2B SPAC merger roughly doubles that private mark and hands Babylon a public listing without an IPO roadshow.
The deal lands at the tail end of the SPAC wave, and the corpus already records how it ends: Babylon went bankrupt in 2023 and was sold for parts, making this listing the peak of the curve rather than a launchpad.
First-order effects
- Babylon converts a $2B-plus private valuation into a $4.2B public listing, giving PIF, Kinnevik and earlier backers tradable equity at a 2x markup on the 2019 Series C.
- The listing puts Babylon's AI diagnostic claims under public-market disclosure and scrutiny for the first time, after years of private fundraising.
Second-order effects
- The deal validates the SPAC as the default exit for AI health startups — an analysis in the coverage counted 14 AI healthcare chatbot startups that had collectively raised $800M+, with Babylon alone at $635M — pressuring peers to seek comparable public valuations.
- Competitors and investors in the AI-health chatbot cluster now have a public comparable at $4.2B, resetting what private rounds in the category can claim to be worth.
Third-order effects
- Babylon's 2023 bankruptcy and asset sale shows the pattern the SPAC route enabled: private and SPAC-era valuations for AI health services ran far ahead of what public markets and customers would ultimately sustain, leaving late entrants holding the loss.
- For healthtech broadly, the arc from $25M Series A to $4.2B listing to liquidation in under a decade becomes the reference case for how AI-diagnosis businesses get priced on ambition before revenue — a repricing the sector's later fundraising had to absorb.
The trend: The SPAC wave offered AI health companies peak-cycle public valuations that outpaced their economics, and Babylon's rise and collapse is the clearest data point in that boom-bust arc.